Comparison of epcoritamab, lenalidomide, and rituximab versus usual care in relapsed/refractory follicular lymphoma.

OncoimmunologyJul 7, 2026 (epub)
Clinical ResearchOncology (Medical)Open access

Lorenzo Falchi, Martin Hutchings, David Tybor et al.

✦ AI-curated · Sources linked

In 30 seconds

This comparative study evaluated the efficacy of epcoritamab combined with lenalidomide and rituximab (R2) versus standard care in patients with relapsed/refractory follicular lymphoma (R/R FL). The analysis included data from 111 patients receiving epcoritamab+R2 and 380 patients receiving R2/chemoimmunotherapy. Epcoritamab+R2 demonstrated significantly higher overall response rates (96.9% vs 80.5%, P < .001) and improved survival outcomes.

Key findings

  • Overall response rate was 96.9% for epcoritamab+R2 compared to 80.5% for R2/CIT (P < .001).
  • Complete response rate was 90.2% for epcoritamab+R2 versus 55.1% for R2/CIT (P < .001).
  • Epcoritamab+R2 improved progression-free survival with a hazard ratio of 0.43 (P < .001).
  • Overall survival was significantly better with epcoritamab+R2, hazard ratio 0.33 (P = .003).

Why it matters

The findings suggest that epcoritamab combined with lenalidomide and rituximab offers a superior treatment option for patients with relapsed/refractory follicular lymphoma, potentially leading to better patient outcomes without the need for chemotherapy.

Source

PubMed · PMID 42415230Free full text on PubMed Central

Published in Oncoimmunology. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.